Fusion Pharmaceuticals Inc (FUSN)

NASDAQ
7.920
-0.240(-2.94%)
  • Volume:
    23,606
  • Bid/Ask:
    7.800/9.000
  • Day's Range:
    7.920 - 8.210

FUSN Overview

Prev. Close
8.16
Day's Range
7.92-8.21
Revenue
-
Open
8.16
52 wk Range
6.607-14.31
EPS
-2.05
Volume
23,606
Market Cap
336.26M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
-
P/E Ratio
-
Beta
-
1-Year Change
-40%
Shares Outstanding
42,456,589
Next Earnings Date
Nov 16, 2021
What is your sentiment on Fusion Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Fusion Pharmaceuticals Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Fusion Pharmaceuticals Inc Company Profile

Fusion Pharmaceuticals Inc Company Profile

Employees
61

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. The Company has developed its Targeted Alpha Therapies (TAT) platform together with its Fast-Clear linker technology. Its technology enables it to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its TAT platform is underpinned by its research and insights into the underlying biology of alpha emitting radiopharmaceuticals as well as its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain and development of imaging diagnostics. The Company’s lead product candidate is FPI-1434, that utilizes Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor I receptor (IGF-1R) with alpha emitting isotope actinium-225.

Read More
  • Interesting company, with a very large market key product. Spin off from government and a University, so it is much more substantive a company than typical start ups. Trading below ipo price, looks like a nice discount for a longer term hold.
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.